Mundipharma biosimilar trastuzumab launches in Europe

May 2, 2018

Mundipharma announces their biosimilar trastuzumab (in-licensed from Celltrion) is available in Europe. This is Mundi’s third biosimilar to be launched in EU, but the second biosimilar TmAb, following MSD’s launch in March 2018.

Print Page Mail Article